Live tape
Top 8, mentions 7d6,727META2,070 mentions▲ +0.06GOOGL1,400 mentions▲ +0.02MUSE633 mentions▲ +0.07NVDA575 mentions▲ +0.08MSFT557 mentions▲ +0.06QQQ511 mentions▲ +0.08SPY494 mentions▲ +0.05TSLA487 mentions▲ +0.06

Equity · Healthcare

PCVX

Vaxcyte, Inc. · NasdaqGS

$56.20 +0.39% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 13 sessions
$62 $54 30 Jun 17 Jul

The line runs $58.15 on 30 June through $56.20 on 17 July, on a scale from $54 to $62. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of PCVX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 13 sessions over that window: $58.15 on 30 June 2026 through $56.20 on 17 July 2026.

Market cap $8.4B
52-week range $30 – $63
Avg volume 295.2K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

PCVX insider trades

SEC Form 4 · last 90 days · newest reported trade 9 Sep 2026
Open-market buys 0
Open-market sells 9
Net sold $3.68M
Non-trade filings 23
Date Insider Type Shares Value
09 Sep 2026 Wassil Jim EVP, Chief Scientific Ofc, COO Sell 1,334 $79K
04 Sep 2026 Wassil Jim EVP, Chief Scientific Ofc, COO Sell 1,381 $84K
01 Sep 2026 Wassil Jim CHIEF OPERATING OFFICER Sell 3,477 $212K
05 Aug 2026 Dhaliwal Harpreet S. Chief Technical Ops Officer Sell 17,000 $935K
03 Aug 2026 GUGGENHIME ANDREW PRESIDENT AND CFO Sell 10,000 $539K
03 Aug 2026 Wassil Jim CHIEF OPERATING OFFICER Sell 2,250 $121K
27 Jul 2026 PICKERING GRANT CHIEF EXECUTIVE OFFICER Sell 18,198 $1.01M
06 Jul 2026 GUGGENHIME ANDREW PRESIDENT AND CFO Sell 10,000 $573K
01 Jul 2026 Wassil Jim CHIEF OPERATING OFFICER Sell 2,250 $127K

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
08 Sep 2026 Cowan Elvia SVP, Finance & CAO Tax withheld 1,327 $80K
08 Sep 2026 Dhaliwal Harpreet S. Chief Technical Ops Officer Tax withheld 7,651 $462K
08 Sep 2026 GUGGENHIME ANDREW PRESIDENT AND CFO Tax withheld 7,155 $432K
08 Sep 2026 PICKERING GRANT CHIEF EXECUTIVE OFFICER Tax withheld 17,056 $1.03M
08 Sep 2026 Wassil Jim EVP, Chief Scientific Ofc, COO Tax withheld 5,459 $330K
04 Sep 2026 Jodar Luis Chief Medical Officer Award 52,632
02 Sep 2026 Cowan Elvia SVP, Finance & CAO Tax withheld 326 $20K
02 Sep 2026 Dhaliwal Harpreet S. Chief Technical Ops Officer Tax withheld 659 $41K
02 Sep 2026 GUGGENHIME ANDREW PRESIDENT AND CFO Tax withheld 1,432 $88K
02 Sep 2026 PICKERING GRANT CHIEF EXECUTIVE OFFICER Tax withheld 3,427 $211K
02 Sep 2026 Wassil Jim CHIEF OPERATING OFFICER Tax withheld 1,432 $88K
01 Sep 2026 Wassil Jim CHIEF OPERATING OFFICER Option exercise 2,250 $12K

Showing the 12 most recent of 23 compensation filings in this window. The figures above count all of them.

PCVX reported financials

SEC EDGAR XBRL

PCVX reported net income of −$766.6M for the fiscal year ended 31 Dec 2025.

Figure Reported Period
Net income −$766.6M 31 Dec 2025 fiscal year
Diluted EPS −$5.63 31 Dec 2025 fiscal year
Total assets $3.1B 30 Jun 2026 at period end
Total equity $2.8B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

PCVX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.97 —
31 Mar 2026 Q1 2026 $-2.30 —
31 Dec 2025 FY 2025 $-5.63 —
30 Sep 2025 Q3 2025 $-1.56 —
30 Jun 2025 Q2 2025 $-1.22 —
31 Mar 2025 Q1 2025 $-1.04 —
31 Dec 2024 FY 2024 $-3.80 —
30 Sep 2024 Q3 2024 $-0.83 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

PCVX institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a PCVX position for the quarter ended 30 Jun 2026 — a combined $239.0M; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
D. E. Shaw & Co. Trimmed −33.6% shares 1,901,872 $110.6M
Maverick Capital Held (±25%) +17.1% shares 1,613,242 $93.8M
Two Sigma Investments Added +146.0% shares 273,876 $15.9M
Millennium Management Trimmed −53.5% shares 136,625 $7.9M
Man Group Added +323.9% shares 81,632 $4.7M
Bridgewater Associates Added +289.2% shares 50,217 $2.9M
AQR Capital Management Added +35.8% shares 34,563 $2.0M
Renaissance Technologies Trimmed −64.1% shares 19,634 $1.1M
Balyasny Asset Management Exited
Baupost Group Exited

Source: SEC EDGAR 13F filings

PCVX fails-to-deliver

SEC CNS data

On 27 Aug 2026, 1,874 shares of PCVX failed to deliver (about $114K).

Settlement date Shares failed Notional % of shares out
27 Aug 2026 1,874 $114K 0.001%
25 Aug 2026 275 $17K <0.001%
20 Aug 2026 38,014 $2.4M 0.026%

Source: SEC fails-to-deliver (CNS) data

Congressional trades in PCVX

STOCK Act disclosures

The most recent congressional trade disclosed in PCVX is a purchase by Gilbert Ray Cisneros, Jr. (house, CA), dated 16 Jul 2026.

Date Member Type Amount
16 Jul 2026 filed 04 Sep 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K
13 May 2026 filed 08 Jun 2026 Gilbert Ray Cisneros, Jr. house · Democrat–CA Purchase $1K–$15K

Source: U.S. House of Representatives financial disclosures